Samsung BioLogics Co Ltd
207940
Company Profile
Business description
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2024, Samsung Biologics had a total production capacity of 754,000 liters, one of the largest in the world. Its CDMO services account for 66.2% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Contact
125, Cheomdan-daero
Yeonsu-gu
Incheon
KORSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5,273
Stocks News & Analysis
stocks
Going into earnings, is Netflix stock a buy, a sell, or fairly valued?
Watching sales growth and the potential for margin expansion, here’s what we think of Netflix stock.
stocks
Bapcor is paying for the sins of its past
Shares plunged over 17% after reporting disappointing results.
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,390.10 | 16.40 | 0.17% |
| CAC 40 | 8,217.68 | 11.61 | 0.14% |
| DAX 40 | 24,229.46 | 29.34 | -0.12% |
| Dow JONES (US) | 46,706.58 | 515.97 | 1.12% |
| FTSE 100 | 9,423.14 | 19.57 | 0.21% |
| HKSE | 26,027.55 | 168.72 | 0.65% |
| NASDAQ | 22,990.54 | 310.57 | 1.37% |
| Nikkei 225 | 49,316.06 | 130.56 | 0.27% |
| NZX 50 Index | 13,377.85 | 32.89 | 0.25% |
| S&P 500 | 6,735.13 | 71.12 | 1.07% |
| S&P/ASX 200 | 9,094.70 | 18.80 | 0.21% |
| SSE Composite Index | 3,916.33 | 52.44 | 1.36% |